Skip to content

AtriCure

US · ATRC #2543 by market cap Listed 1970
55.39 +1.28 +2.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 5.43 Expensive vs history 87th percentile
5-year average 4.07 · #38 of 51 in Medical Instruments & Supplies
P/E ratio 183.35 Expensive vs history 94th percentile
5-year average -23.79 · forward 207.46 · #25 of 27 in Medical Instruments & Supplies
P/S ratio 4.91 In line with history 58th percentile
5-year average 5.10 · forward 4.36 · #37 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
AtriCure (ATRC) 2.82B 178.68 5.29 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value57.52 Economic moatNone UncertaintyHigh

Trading 3.9% below Morningstar's fair value estimate.

Fair value

AtriCure Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% discount to our quantitative fair value estimate of $57.52 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's solid growth bolsters our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its EBITDA per share growth, which ranks in the top 30% globally. This suggests rapid margin expansion is underway, or new markets are being tapped, which contributes to our view that shares are cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 20.5%, for example, falls in the bottom 20% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

AtriCure discussion 0 comments

Add a comment